CLN-049 has received FDA fast track designation for relapsed or refractory AML, highlighting its potential as a novel immunotherapy option. Initial phase 1 study results demonstrate meaningful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback